Get notified when FBRX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Substantial and Immediate Dilution of $15.48 Per Share (new) — New investors pay $26.27 per share but receive only $10.79 in net tangible book value per share, an immediate dilution of $15.48 per share.
  • Even If This Offering Is Successful, We Will Require Substantial Additional Capital to Finance Our Operations. (new) — The company explicitly states that the offering proceeds plus existing cash may not be sufficient to fund clinical programs through regulatory approval and commercialization, indicating a going concern risk.
NASDAQ: FBRX Forte Biosciences, Inc. 424B5

Forte Biosciences prices $141M primary offering at $26.27/share; net proceeds $140.3M

Filed April 9, 2026 · ~1 min read

Key Changes

  • high

    Forte Biosciences is selling 5,709,936 shares at $26.27 per share, raising $141.0 million before expenses.

    The Offering verify on EDGAR →
  • high

    Net proceeds to the company are estimated at $140.3 million, after underwriting discounts and expenses.

    Use of Proceeds verify on EDGAR →
  • high

    New investors face immediate dilution of $15.48 per share, as net tangible book value per share after the offering is $10.79.

    Dilution verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (SAR 10-Q) is open in full — no account needed.

Partner

Trade FBRX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify